Federal Register #2026-21143

USITC Investigations of CBS Imports from China

The U.S. International Trade Commission is investigating imports of CBS from China for potential harm to U.S. industry. - Government agency: U.S. International Trade Commission (USITC), Office of Investigations. - Purpose: Final-phase antidumping and countervailing duty investigations into imports of n-cyclohexylbenzothiazole-2-sulfenamide (CBS) from China, under Investigation Nos. 701-TA-797 and 731-TA-1793. This is an investigative notice, not a request to buy products or services. - Product under investigation: CBS, CAS No. 95-33-0, in powder, oiled powder, granule, or solution form; commingled CBS is also included. No purchase quantity or commercial part number is specified. - Other names include Accelerator CZ, CBTS, Thiohexam, HIP4, Curax, DURAX, Conaca, Conach, Conacs, and Celacs. - Named company: LANXESS Corporation requested the investigations. The notice does not identify it as the product’s manufacturer or supplier. - Key findings and scope: The Department of Commerce preliminarily determined that imports are subsidized; its preliminary determination on whether they are sold below fair value was pending. The USITC will assess whether the imports materially injure or threaten to injure a U.S. industry, or materially retard the establishment of one.

Description

The U.S. International Trade Commission has scheduled the final phase of antidumping and countervailing duty investigations concerning imports of n-cyclohexylbenzothiazole-2-sulfenamide (CBS) from China. The investigations will determine whether those imports materially injure or threaten material injury to a U.S. industry, or materially retard the establishment of an industry. Commerce preliminarily determined that the imports are subsidized, while its preliminary determination on the allegation that they are sold in the United States at less than fair value is pending. The notice also describes the product scope and sets out procedures and deadlines for participation, submissions, and the hearing.

View original listing